G Mezquida1, G Savulich2, C Garcia-Rizo3, M P Garcia-Portilla4, A Toll5, L Garcia-Alvarez6, J Bobes4, A Mané5, M Bernardo7, E Fernandez-Egea8. 1. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Spain. 2. Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom. 3. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 4. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Department of Psychiatry, University of Oviedo, Spain. 5. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Institut de Neuropsiquiatria i Adiccions, Parc de Salut Mar, Barcelona, Spain; Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. 6. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain. 7. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medicine, University of Barcelona, Spain. 8. Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom. Electronic address: ef280@cam.ac.uk.
Abstract
BACKGROUND: We investigated whether negative symptoms, such as poor motivation or anhedonia, were associated with higher body mass index (BMI) in stable patients with schizophrenia chronically treated with antipsychotic medication. METHODS: 62 olanzapine- or clozapine-treated patients with illness duration of at least four years were selected from an international multicenter study on the characterization of negative symptoms. All participants completed the Brief Negative Symptom Scale (BNSS) and the Positive and Negative Syndrome Scale (PANSS). Bivariate correlations between BMI and negative symptoms (BNSS) were explored, as well as multiple regression analyses. We further explored the association of two principal component factors of the BNSS and BMI. Subsidiary analyses re-modeled the above using the negative symptoms subscale of the PANSS and the EMSLEY factor for negative symptoms for convergent validity. RESULTS: Lower negative symptoms (BNSS score) were associated with higher BMI (r=-0.31; p=0.015). A multiple regression analysis showed that negative symptoms (BNSS score) and age were significant predictors of BMI (p=0.037). This was mostly driven by the motivation/pleasure factor of the BNSS. Within this second factor, BMI was negatively associated with anhedonia (r=-0.254; p=0.046) and asociality (r=-0.253; p=0.048), but not avolition (r=-0.169; p=0.188). EMSLEY score was positively associated with BNSS (r=0.873, p<0.001), but negatively associated with BMI (r=-0.308; p=0.015). The association between PANSS and BMI did not reach significance (r=-224, p=0.080). CONCLUSIONS: We conclude that lower negative symptoms were associated with higher BMI (assessed using both the BNSS and EMSLEY) in chronic stable schizophrenia patients, mostly due to lower anhedonia and asociality levels.
BACKGROUND: We investigated whether negative symptoms, such as poor motivation or anhedonia, were associated with higher body mass index (BMI) in stable patients with schizophrenia chronically treated with antipsychotic medication. METHODS: 62 olanzapine- or clozapine-treated patients with illness duration of at least four years were selected from an international multicenter study on the characterization of negative symptoms. All participants completed the Brief Negative Symptom Scale (BNSS) and the Positive and Negative Syndrome Scale (PANSS). Bivariate correlations between BMI and negative symptoms (BNSS) were explored, as well as multiple regression analyses. We further explored the association of two principal component factors of the BNSS and BMI. Subsidiary analyses re-modeled the above using the negative symptoms subscale of the PANSS and the EMSLEY factor for negative symptoms for convergent validity. RESULTS: Lower negative symptoms (BNSS score) were associated with higher BMI (r=-0.31; p=0.015). A multiple regression analysis showed that negative symptoms (BNSS score) and age were significant predictors of BMI (p=0.037). This was mostly driven by the motivation/pleasure factor of the BNSS. Within this second factor, BMI was negatively associated with anhedonia (r=-0.254; p=0.046) and asociality (r=-0.253; p=0.048), but not avolition (r=-0.169; p=0.188). EMSLEY score was positively associated with BNSS (r=0.873, p<0.001), but negatively associated with BMI (r=-0.308; p=0.015). The association between PANSS and BMI did not reach significance (r=-224, p=0.080). CONCLUSIONS: We conclude that lower negative symptoms were associated with higher BMI (assessed using both the BNSS and EMSLEY) in chronic stable schizophreniapatients, mostly due to lower anhedonia and asociality levels.
Authors: Christian Núñez; Christian Stephan-Otto; Judith Usall; Miquel Bioque; Antonio Lobo; Ana González-Pinto; Laura Pina-Camacho; Eduard Vieta; Josefina Castro-Fornieles; Roberto Rodriguez-Jimenez; Anna Butjosa; Joost Janssen; Bibiana Cabrera; Mara Parellada; Miquel Bernardo Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Shih-Hsien Lin; Huai-Hsuan Tseng; Hsin Chun Tsai; Mei Hung Chi; I Hui Lee; Po See Chen; Kao Chin Chen; Yen Kuang Yang Journal: Clin Psychopharmacol Neurosci Date: 2021-02-28 Impact factor: 2.582
Authors: Krzysztof Kowalski; Bogna Bogudzińska; Bartłomiej Stańczykiewicz; Patryk Piotrowski; Tomasz Bielawski; Jerzy Samochowiec; Krzysztof Szczygieł; Piotr Plichta; Błażej Misiak Journal: J Clin Med Date: 2022-01-23 Impact factor: 4.241